Solen Therapeutics Reports Director Changes and Compensation Adjustments
Ticker: SLNO · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $10 billion, $915 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
TL;DR
Solen Therapeutics shakes up the board and adjusts exec pay.
AI Summary
Solen Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on the departure of a director, election of a new director, and changes in officer compensation. The filing also includes other events and financial statements/exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officer compensation can indicate internal shifts that may affect company direction and stability.
Key Numbers
- 001-36593 — Commission File Number (Identifies the company's SEC filings)
- 77-0523891 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Solen Therapeutics, Inc. (company) — Registrant
- October 13, 2025 (date) — Date of earliest event reported
- October 14, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 100 Marine Parkway, Suite 400 Redwood City, CA 94065 (address) — Principal executive offices
FAQ
Who departed from the board of directors at Solen Therapeutics?
The filing indicates the departure of a director, but the specific name is not provided in the provided text.
Who was elected as a new director to the Solen Therapeutics board?
The filing mentions the election of a new director, but the specific name is not detailed in the provided text.
What specific compensatory arrangements for officers are being reported?
The filing notes changes in compensatory arrangements for certain officers, but the details are not specified in the provided text.
What is the principal executive office address for Solen Therapeutics?
The principal executive offices are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
What is the SIC code for Solen Therapeutics?
The Standard Industrial Classification (SIC) code for Solen Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 969 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2025-10-14 06:05:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $10 billion — by Merck & Co., Inc. for approximately $10 billion in October 2025. From January 2018 unti
- $915 million — edish Orphan Biovitrum (Sobi) for up to $915 million in November 2019, Mr. Hahn served as CF
Filing Documents
- d847935d8k.htm (8-K) — 29KB
- d847935dex991.htm (EX-99.1) — 12KB
- 0001193125-25-237854.txt ( ) — 159KB
- slno-20251013.xsd (EX-101.SCH) — 3KB
- slno-20251013_lab.xml (EX-101.LAB) — 18KB
- slno-20251013_pre.xml (EX-101.PRE) — 11KB
- d847935d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits Exhibit No. Description 99.1 Press release issued by Soleno Therapeutics, Inc. dated October 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: October 14, 2025 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer